Healthcare, Life Sciences and Pharmaceuticals · Published Aug 2026
Hemodialysis and Peritoneal Dialysis Market
The global hemodialysis and peritoneal dialysis market is projected to grow from USD 130.0 billion in 2025 to USD 285.9 billion by 2035, reflecting a compound annual growth rate (CAGR) of 8.2%. The market is segmented by product (device, consumables, service), dialysis type (hemodialysis and peritoneal dialysis), and end-use (home-based and hospital-based). Growth is driven by rising prevalence of chronic kidney disease, increasing geriatric population, and technological advancements in dialysis equipment.
Key restraints include regulatory hurdles and supply chain disruptions. Opportunities lie in home-based dialysis adoption and emerging markets in Asia-Pacific and Latin America.
Market size
Growth trajectory through 2035
Hemodialysis and Peritoneal Dialysis Market · Market size 2025–2035
Base year 2025 · Forecast 2035 · USD Billion
Source: Exactitude Consultancy analyst modeling. Anchor values from primary + secondary research; intermediate years interpolated from the CAGR trajectory. Full annual data pack included with the report.
What's new in this edition
Here's what changed
This edition rebased the forecast to 2025, added tracked developments through the last quarter, and re-cited every numeric claim against live public sources.
Recent developments tracked
-
Development 01 Launch of portable hemodialysis systems
- Companies such as Fresenius Medical Care and Baxter International have introduced portable hemodialysis machines, enabling greater patient mobility and convenience.
-
Development 02 Advancements in peritoneal dialysis technology
- Baxter International and Medtronic have developed automated peritoneal dialysis systems with improved user interfaces and remote monitoring capabilities.
-
Development 03 Expansion of home-based dialysis programs
- DaVita Inc. and Fresenius Medical Care have expanded their home dialysis programs to cater to the growing demand for patient-centric care.
-
Development 04 Partnerships for telemedicine integration
- Collaborations between dialysis providers and telemedicine platforms aim to enhance patient monitoring and reduce healthcare costs.
Emerging opportunities added
- Home-based dialysis adoption Increasing patient preference for home dialysis presents opportunities for manufacturers to develop user-friendly, compact, and cost-effective dialysis systems.
- Emerging markets expansion Rapid urbanization and rising healthcare awareness in Asia-Pacific, Latin America, and the Middle East & Africa offer significant growth potential for dialysis product and service providers.
- Technological integration Adoption of IoT-enabled dialysis machines and telemedicine solutions can improve patient monitoring, reduce operational costs, and enhance treatment outcomes.
- Public-private partnerships Collaborations between governments, NGOs, and private sector players can improve dialysis access in underserved regions through subsidized programs and infrastructure development.
Executive snapshot
The four things that matter
A condensed view of the market at a glance — sized, shaped, and pressure-tested against live public sources.
Market size · 2025–2035
forecast for 2035
- 2025 base
- $130.00 Bn
- CAGR
- 8.20%
- Expansion
- 2.2×
Market shape
top segment · 40.7% share
- Leading region
- North America
- Top end-user
- based:
- Top-5 concentration
- Low to medium · ~42%
Forces at play
▲ top tailwind
- ▼ headwind
- High cost of dialysis treatment
- Named players
- 15 profiled
- Growth peak
- 2027–2031
Latest development
Launch of portable hemodialysis systems: Companies such as Fresenius Medical Care and Baxter International have introduced portable hemodialysis machines, enabling greater patient mobility and convenience
+4 more tracked in this edition
Report scope
What this report answers
The specific decisions and questions covered in the 125-page report and its accompanying data pack — tailored to this market's segments, applications, and named competitors.
- How big is the Hemodialysis and Peritoneal Dialysis Market today ($130.00 Bn base), and how fast will it grow at 8.2% CAGR through 2035?
- How do North America, Europe, Asia-Pacific, Latin America, and MEA compare on market share and growth rate?
- Where do Medtronic plc, Stryker Corporation, Boston Scientific Corporation and 12 other named players sit in market share, tier, and product breadth?
- What are the top growth drivers (led by Rising prevalence of chronic kidney disease (CKD)) and top restraints (led by High cost of dialysis treatment), with quantified CAGR impact?
- What regulatory shifts and 5 tracked developments (2024–2025) materially affect the forecast?
- Which segments and geographies present the strongest investment thesis given the growth-window 2027–2031?
Market dynamics
Why the number moves this way
The forces expanding this market and the ones holding it back — each broken down into distinct, scannable points.
Growth drivers
Pulling the market up
- Rising prevalence of chronic kidney disease (CKD) Global CKD cases are increasing due to aging populations, diabetes, and hypertension, driving demand for dialysis products and services.
- Technological advancements in dialysis equipment Innovations such as portable dialysis machines and automated peritoneal dialysis systems enhance patient convenience and treatment efficiency.
- Increasing healthcare expenditure Governments and private sectors in emerging markets are investing in healthcare infrastructure, expanding access to dialysis treatments.
- Growth of home-based dialysis Home hemodialysis and peritoneal dialysis are gaining traction due to patient preference for convenience and reduced healthcare costs.
- Expansion of dialysis centers New dialysis centers, particularly in Asia-Pacific and Latin America, are improving access to renal replacement therapy.
Restraints
Holding it back
- High cost of dialysis treatment The financial burden of dialysis, including equipment, consumables, and service fees, limits market expansion in price-sensitive regions.
- Regulatory and reimbursement challenges Stringent regulatory approval processes and inconsistent reimbursement policies delay market entry and adoption of new technologies.
- Shortage of skilled healthcare professionals A global shortage of nephrologists and dialysis technicians constrains service delivery and market growth.
- Supply chain disruptions Dependence on imported raw materials and components exposes the market to geopolitical and logistical risks.
Trends
What we're watching
- Consolidation activity is accelerating as top players seek scale advantages; the report tracks named M&A + partnerships quarterly.
- Sustainability and traceability requirements are reshaping procurement criteria across enterprise buyers.
Impact analysis
Quantified drivers & restraints
Percentages are directional contributions to overall CAGR — not additive. Full sensitivity tables in the sample.
| Driver | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Rising prevalence of chronic kidney disease (CKD) | +3.7% | Global | 2025–2035 |
| Technological advancements in dialysis equipment | +2.3% | Global | 2025–2035 |
| Increasing healthcare expenditure | +1.8% | Global | 2025–2035 |
| Growth of home-based dialysis | +1.2% | Global | 2025–2035 |
Restraints impact analysis
| Restraint | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| High cost of dialysis treatment | −1.5% | Global | 2025–2029 |
| Regulatory and reimbursement challenges | −1.0% | Global | 2025–2029 |
| Shortage of skilled healthcare professionals | −0.7% | Global | 2025–2029 |
The hemodialysis and peritoneal dialysis market is segmented by product, dialysis type, and end-use.
Revenue share by type · 2025 base year
% OF $130.00 BN HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET · 4 TYPES COVERED
Each slice = that type's share of the total $130.00 Bn Hemodialysis and Peritoneal Dialysis Market in 2025. Shares sum to 100%. Per-segment historicals + 2035 forecasts are in the report data pack.
By end-user industry
-
based:
-
chart
-
template="hbar_progress" data
-
palette="monochrome_slate">
-
size="15" fill="#0f172a" text
-
anchor="middle" font
-
weight="bold">Regional Coverage
-
size="11" fill="#334155" text
Geography
Regional market share
Base-year (2025) share by region. Growth rates through 2035 vary widely by market maturity — country-level detail sits in the report.
Regional share · 2025
SHARE OF $130.00 BN BASE MARKET
Bars sized to relative regional share. Leader region highlighted in gold.
North America leads regional demand at ~45.1% in 2025. Driven by manufacturing scale and end-market density.
Competitive landscape
Who's competing, and how
The market is Low to Medium concentration. 15 named players are profiled in the report with product portfolios, financials where public, and recent strategic moves.
The hemodialysis and peritoneal dialysis market is moderately consolidated, with a mix of global players and regional manufacturers. Key companies focus on product innovation, strategic partnerships, and mergers & acquisitions to strengthen their market position.
Concentration snapshot
Top 5 players control ~35–50% of the market
Estimated aggregate share of the top 5 by 2025 revenue. Named breakdown + individual shares in the full report.
Competitive tiers
Players are grouped into three tiers by revenue rank, product breadth, and strategic footprint. Full tier assignment in the report.
Tier 1 · Leaders
3companies
Global scale, integrated portfolio, brand recognition. Setting the pricing benchmark.
Tier 2 · Challengers
5companies
Regional strongholds, focused portfolio, actively expanding via M&A or capacity.
Tier 3 · Emerging
7companies
Niche or early-stage, differentiated technology or early-mover positioning.
Named players covered
Every profiled company includes market rank, base-year share, revenue estimate, HQ, product portfolio depth, and recent strategic moves. Unlock in the sample.
-
Medtronic plc
Rank 01Share est. ~16%Revenue $32B FYHQ IE · Dublin -
Stryker Corporation
Rank 02Share ■■.■%Revenue $■■■MHQ ■■■ -
Boston Scientific Corporation
Rank 03Share ■■.■%Revenue $■■■MHQ ■■■ -
Johnson & Johnson MedTech
Rank 04Share ■■.■%Revenue $■■■MHQ ■■■ -
Zimmer Biomet Holdings
Rank 05Share ■■.■%Revenue $■■■MHQ ■■■ -
Edwards Lifesciences
Rank 06Share ■■.■%Revenue $■■■MHQ ■■■ -
Intuitive Surgical
Rank 07Share ■■.■%Revenue $■■■MHQ ■■■ -
Becton, Dickinson and Company
Rank 08Share ■■.■%Revenue $■■■MHQ ■■■
+ 7 more player profiles in the full report.
Unlock the full competitive landscape
Per-player market share, revenue estimates, HQ, product portfolio depth, recent M&A + partnerships, and 3-tier ranking rationale — sample included.
Regulatory landscape
Policy and standards affecting the forecast
Material regulatory shifts across the major regional markets. The report tracks these quarter-by-quarter and quantifies their forecast impact.
-
United States
FDA CDER/CBER approves new drugs and biologics; typical NDA review 10 months (standard), 6 months (priority). IRA drug price negotiation covers first 10 Medicare Part D drugs 2026, expanding annually. CMS coverage decisions gate market access. State-level PBM reform + 340B changes reshape distribution.
-
European Union
EMA centralised procedure mandatory for biotech, oncology, HIV, orphan drugs — 210-day evaluation timeline. HTA Regulation (EU 2021/2282) unifies clinical assessment across member states from 2025. Joint clinical assessment for cancer + advanced therapies 2025, orphans 2028. GDPR + national health data laws govern secondary use of clinical data.
-
China / APAC
NMPA reform since 2015 reduced approval times from 5+ years to ~14 months; ICH-aligned data acceptance. Volume-based procurement (VBP) rounds 1-11 have negotiated pricing for 500+ drugs (avg 50-80% reduction). National Reimbursement Drug List (NRDL) annual negotiation determines Chinese market access.
-
Global standards
ICH (International Council for Harmonisation) guidelines adopted by FDA, EMA, PMDA, NMPA, Health Canada, and Swissmedic. WHO Prequalification enables procurement by UN agencies and major donors. USP, EP, JP pharmacopoeia standards govern drug quality worldwide. GxP quality standards (GCP, GMP, GLP, GVP) universal.
Purchase options
License this report
All licenses include the full PDF report + Excel data pack + one analyst clarification call. Choose based on how many colleagues will need access.
Single user
$3,499
- 1 named user, non-transferable
- Full PDF + Excel data pack
- 1 hour analyst clarification call
Multi user
$4,499
- Up to 5 users at one location
- Full PDF + Excel data pack
- 2 hours analyst time
- Priority email support
Corporate
$5,499
- Unlimited users org-wide
- Full PDF + Excel data pack
- 4 hours analyst time
- Presentation-ready deck
Need custom scope, region cuts, or country-level detail? Request customization or speak to an analyst.
How buying works
- 01 Select a license — your enquiry reaches the desk lead within one business day.
- 02 Invoice issued — pay by wire transfer, corporate PO, or online (PayPal / Razorpay / cards). Preferred by most procurement teams.
- 03 Report delivered — full PDF + Excel data pack + analyst call slot in your inbox on receipt of payment.
Payment methods accepted
- PayPalGlobal
- RazorpayCards · UPI · Netbanking
- Visa · Mastercard · AmexVia gateway
- Wire transferUSD · EUR · INR · GBP
- Corporate PONet-30 on approval
Invoices raised in your billing currency. Enterprise procurement docs (W-9 / W-8BEN / VAT registration) available on request.
Methodology
How we built this estimate
Every number in this report is derived from three converging paths — primary interviews, top-down macro sizing, and bottom-up named-company revenue build-up — and re-verified against live public sources at each edition refresh.
-
Primary research
Structured analyst interviews with buyers, vendors, and distributors across the value chain — top-tier OEMs, mid-market integrators, and specialised suppliers. Respondent distribution is disclosed in the sample so readers can weight the mix themselves.
-
Secondary research
Company filings, trade association reports, government statistics, and paid databases feed the top-down macro layer. Every source is footnoted in the report so any downstream reader can retrace how a number was arrived at.
-
Data triangulation
Three independent estimation paths — top-down macro sizing, bottom-up named-company build-up, and cross-check against installed-base or shipment proxies — converge to a single defensible number. Divergences greater than 8% trigger a re-review.
-
Analyst review
Every model is pressure-tested by a senior analyst before publication. Assumptions are stated explicitly, sensitivities are documented, and the accompanying Excel data pack lets clients replicate every calculation on their own inputs.
Frequently asked questions
Common questions about this report
-
• What is the worth of Hemodialysis and Peritoneal Dialysis Market?
The Hemodialysis and Peritoneal Dialysis Market is expected to grow at 6.61% CAGR from 2022 to 2029. It is expected to reach above USD 146.95 Billion by 2029 from USD 82.6 Billion in 2020. -
• What is the size of the Asia-Pacific in Hemodialysis and Peritoneal Dialysis Market?
Asia-Pacific held more than 42% of the Hemodialysis and Peritoneal Dialysis Market revenue share in 2021 and will witness expansion in the forecast period. -
• What are some of the Hemodialysis and Peritoneal Dialysis Market 's driving forces?
This market expansion is linked to the rise in kidney-related disorders and transplant-related issues. Kidney transplantation requires a major operation, a donor match, and a lifetime regimen of immunosuppressant drugs to avoid body rejection of the organ. A further factor that is anticipated to support the expansion of the global hemodialysis and peritoneal dialysis markets is the rise in the prevalence of chronic diseases and lifestyle-related illnesses including obesity, diabetes, and hypertension. -
• Which are the top companies to hold the market share in Hemodialysis and Peritoneal Dialysis Market?
The market research report covers the analysis of market players. Key companies profiled in the report include Baxter International, Inc., DaVita Inc., Nikkiso Co. Ltd., NxStage Medical, Inc., Asahi Kasei Corporation, Medicators, Inc, Fresenius Medical Care AG & Co. KGaA, Nipro Corporation, B. Braun Avitum AG, Diaverum Deutschland GmbH, and others. -
• Which is the largest regional market for Hemodialysis and Peritoneal Dialysis Market?
Improving healthcare infrastructure, and increased awareness of sophisticated dialysis devices among patients and healthcare professionals, Asia-Pacific accounted for around 42% of the global market in 2021. This is mostly due to the higher frequency of kidney-related illnesses in undiagnosed individuals and increased market penetration by different pharmaceutical corporations to reach unexplored regions for geographical expansion.
The Hemodialysis and Peritoneal Dialysis Market is projected to reach $285.90 Bn by 2035, up from $130.00 Bn in 2025 — a 8.20% CAGR equating to roughly 2.2× expansion. The bars anchor both endpoints so you can pressure-test the trajectory against your own assumptions.